Grifols advised by Osborne Clarke on Shanghai RAAS deal
Barcelona-headquartered healthcare company Grifols was advised by Osborne Clarke on the signing of a “strategic alliance agreement” with China-based plasma derivatives company Shanghai RAAS.
Under the terms of the agreement, Grifols and Shanghai RAAS will manufacture, market and develop plasma products and transfusion products in the Chinese market.
Shanghai RAAS will also become Grifols’ exclusive distributor of these products in China.
Under the terms of the alliance, Grifols will acquire a 26.2 per cent stake in Shanghai RAAS in exchange for a non-majority share in Grifols Diagnostics Solutions (45 per cent economic and 40 per cent voting rights).
Grifols also received legal advice from Proskauer Rose and JunHe on the deal.
